Pulmonary Drug Delivery Systems Market, By Product Type (Nebulizers, MDIs, DPIs), By Application (Asthma, COPD, Cystic Fibrosis), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportun

Pulmonary Drug Delivery Systems Market, By Product Type (Nebulizers, MDIs, DPIs), By Application (Asthma, COPD, Cystic Fibrosis), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Orally inhaled and nasal drug products (OINDPs) are the products which include metered dose (MDIs), dry powder inhalers (DPIs), nasal sprays and nebulizers. According to FDA, respiratory inhalers are classified under Class II medical devices. All inhaled products have to undergo mandatory test for extractables, leachables and microbial contaminants. Specific tests for OINDPs include aerodynamic particle size distribution (APSD) and delivered dose uniformity (DDU). These tests are regarded as key parameters for assessing performance of the OINDPs. In addition, nasal sprays and MDIs are supplemented by tests to monitor the performance of the actuator and metering valve such as plume geometry and spray pattern.

Restraints of the Global Pulmonary Drug Delivery Systems Market
Major factors hampering the growth of the pulmonary drug delivery systems market during the forecast period constitutes of stringent regulations, and complications in use.
Key features of the study:
This report provides in-depth analysis of the global pulmonary drug delivery systems market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021, as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
It profiles leading players in the global pulmonary drug delivery systems market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include 3M Health Care, Allied Healthcare Products, Inc., AstraZeneca plc, Boehringer Ingelheim, CareFusion Corporation, GF Health Products, Inc., GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Omron Healthcare, Inc., Glenmark Pharmaceuticals, PARI Respiratory Equipment, Inc., and Philips Healthcare.
Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
The global pulmonary drug delivery systems market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.
Detailed Segmentation
Global Pulmonary Drug Delivery Systems Market, By Product Type:
Nebulizers
MDIs
DPIs
Global Pulmonary Drug Delivery Systems Market, By Application:
Asthma
COPD
Cystic Fibrosis
Global Pulmonary Drug Delivery Systems Market, By Geography:
North America
By Product Type
Nebulizers
MDIs
DPIs
By Application
Asthma
COPD
Cystic Fibrosis
By Country:
U.S.
Canada
Europe
By Product Type
Nebulizers
MDIs
DPIs
By Application
Asthma
COPD
Cystic Fibrosis
By Country:
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
By Product Type
Nebulizers
MDIs
DPIs
By Application
Asthma
COPD
Cystic Fibrosis
By Country:
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
By Product Type
Nebulizers
MDIs
DPIs
By Application
Asthma
COPD
Cystic Fibrosis
By Country
Brazil
Argentina
Mexico
Rest of LATAM
Middle East:
By Product Type
Nebulizers
MDIs
DPIs
By Application
Asthma
COPD
Cystic Fibrosis
By Country:
GCC
Israel
Rest of Middle East
Africa
By Product Type
Nebulizers
MDIs
DPIs
By Application
Asthma
COPD
Cystic Fibrosis
By Country/Region:
Central Africa
South Africa
North Africa
Company Profiles
3M Health Care*
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
Allied Healthcare Products, Inc.
AstraZeneca plc
Boehringer Ingelheim
CareFusion Corporation
GF Health Products, Inc.
GlaxoSmithKline plc
Merck & Co., Inc.
Novartis AG
Omron Healthcare, Inc.
Glenmark Pharmaceuticals
PARI Respiratory Equipment, Inc.
Philips Healthcare
“*” marked represents similar segmentation in other categories in the respective section.